Taxane-induced scleroderma

British Journal of Dermatology

Volumn 156, Issue 2, 2007, Pages 363-367

  Itoh, M ^a   Yanaba, K ^a   Kobayashi, T ^a   Nakagawa, H ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Docetaxel; Paclitaxel; Scleroderma; Sclerosis; Systemic sclerosis; Taxane

Indexed keywords

COLLAGEN; DOCETAXEL; DOXORUBICIN; PACLITAXEL; PREDNISOLONE; STEROID; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BLOOD EXAMINATION; BREAST CANCER; CANCER CHEMOTHERAPY; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE COURSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; METASTASIS; MONOCYTE; MULTIPLE CYCLE TREATMENT; PERIPHERAL EDEMA; PRIORITY JOURNAL; SCLERODERMA; SIDE EFFECT; SKIN BIOPSY; SKIN FIBROSIS; STEROID THERAPY; SYSTEMIC SCLEROSIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; SCLERODERMA, LOCALIZED; TAXOIDS;

EID: 33846213143     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07597.x     Document Type: Article

References (26)

1. Schiff PB, Fant J, Horwits SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 227:665-7.
2. Pazdur R, Kudelka AP, Kavanagh JJ et al. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 1993; 19:351-86.
3. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997; 57:229-33.
4. Clements PJ, Lachenbrush PA, Seibold J et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in three independent studies. J Rheumatol 1993; 20:1892-6.
5. Yanaba K, Hasegawa M, Takehara K, Sato S. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol 2004; 31:1112-20.
6. Battafarano DF, Zimmerman GC, Older SA et al. Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases. Cancer 1995; 76:110-15.
7. Cleveland MG, Ajaikumar BS, Reganti R. Cutaneous fibrosis induced by docetaxel: a case report. Cancer 2000; 88:1078-81.
8. Hassett G, Harnett P, Manolios N. Scleroderma in association with the use of docetaxel (Taxotere) for breast cancer. Clin Exp Rheumatol 2001; 19:197-200.
9. Lauchli S, Trueb RM, Fehr M, Hafner J. Scleroderma-like drug reaction to paclitaxel (Taxol). Br J Dermatol 2002; 147:619-21.
10. Kupfer I, Balguerie X, Courville P et al. Scleroderma-like cutaneous lesions induced by paclitaxel: a case study. J Am Acad Dermatol 2003; 48:279-81.
11. De Angelis R, Bugatti L, Cerioni A et al. Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer. Clin Rheumatol 2003; 22:49-52.
12. Farrant PB, Mortimer PS, Gore M. Scleroderma and the taxanes. Is there really a link? Clin Exp Dermatol 2004; 29:360-2.
13. Zimmerman GC, Keeling JH, Burris HA et al. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 1995; 131:202-6.
14. Taxol (Paclitaxel) [Package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 1994.
15. Bronstad A, Berg A, Reed RK. Effects of the taxanes paclitaxel and docetaxel on edema formation and interstitial fluid pressure. Am J Physiol Heart Circ Physiol 2004; 287:963-8.
16. Semb KA, Aamdal S, Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 1998; 16:3426-32.
17. Sato S. Abnormalities of adhesion molecules and chemokines in scleroderma. Curr Opin Rheumatol 1999; 11:503-7.
18. Sharpe RJ, Margolis RJ, Askari M et al. Induction of dermal and subcutaneous inflammation by recombinant cachectin/tumor necrosis factor (TNF alpha) in the mouse. J Invest Dermatol 1988; 91:353-7.
19. Shi-Wen X, Panesar M, Vancheeswaran R et al. Expression and shedding of intercellular adhesion molecule 1 and lymphocyte function-associated antigen 3 by normal and scleroderma fibroblasts. Effects of interferon-gamma, tumor necrosis factor alpha, and estrogen. Arthritis Rheum 1994; 37:1689-97.
20. Gruschwitz MS, Vieth G. Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon-gamma and tumor necrosis factor alpha in the early disease stage. Arthritis Rheum 1997; 40:540-50.
21. Hasegawa M, Sato S, Fujimoto M et al. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol 1998; 25:308-13.
22. Hasegawa M, Sato S, Ihn H, Takehara K. Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology (Oxford) 1999; 38:612-17.
23. Saito E, Fujimoto M, Hasegawa M et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002; 109:1453-62.
24. Duncan MR, Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 1991; 97:686-92.
25. Bogdan C, Ding A. Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages. J Leukoc Biol 1992; 52:119-21.
26. Tsavaris N, Kosmas C, Vadiaka M et al. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 2002; 87:21-7.